Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension

British Journal of Pharmacology

Volumn 137, Issue 8, 2002, Pages 1187-1194

  Murray, Fiona ^a   MacLean, Margaret R ^b   Pyne, Nigel J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CAMP; Cardiovascular disease; CGMP; Genes; Hypertension; NF B; Phosphodiesterase; Pulmonary

Indexed keywords

BROMO CYCLIC AMP; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DERIVATIVE; CYCLIC GMP; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETONE DERIVATIVE; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 3A; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE V; SIGUAZODAN; TOSYLLEUCYLCHLORO KETONE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPOXIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE; TISSUE HOMOGENATE; WESTERN BLOTTING;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CELL LINE; CYCLIC AMP; CYCLIC GMP; HUMANS; HYPERTENSION, PULMONARY; MALE; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; RATS; RATS, WISTAR; TOSYLLYSINE CHLOROMETHYL KETONE;

EID: 12244282450     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704984     Document Type: Article

References (39)

1. Aziz, S.M., Toborek, M., Hennig, B., Endean, E. & Lipke, D.W. (1997). Polyamine regulatory processes and oxidative stress in monocrotaline-treated pulmonary artery endothelial cells. Cell Biol. Int., 21, 801-812.
2. Beavo, J.A. (1995). Cyclic nucleotide phosphodiesterase-functional implications of multiple isoforms. Physiol. Rev., 75, 725-748.
3. Black, S.M., Sanchez, L.S., Mata-Greenwood, E., Bekker, J.M., Steinhorn, R.H. & Fineman, J.R. (2001). SGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol., 281, L1051-L1057.
4. Burns, F., Rodger, I.W. & Pyne, N.J. (1992). The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase in guinea-pig lung. Biochem. J., 283, 487-491.
5. Channick, R.N. & Rubin, L.J. (2000). Combination therapy for pulmonary hypertension: A glimpse into the future? Crit. Care Med., 28, 896-897.
6. Chiarugi, V., Magnelli, L., Chiarugi, A. & Gallo, O. (1999). Hypoxia induces pivotal tumor angiogenesis control factors including p53, vascular endothelial growth factor and the NFkappaB-dependent inducible nitric oxide synthase and cyclooxygenase-2. J. Cancer Res. Clin. Oncol., 125, 525-528.
7. Cohen, A.H., Hanson, K., Morris, K, Fouty, B., McMurty, I.F., Clarke, W. & Rodman, D.M. (1996). Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest., 97, 172-179.
8. Dukarm, R.C., Morin, III F.C., Russell, J.A. & Steinhorn, R.M. (1998). Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn with persistent pulmonary hypertension. Ped. Res., 44, 831.
9. FISHMAN, A.L. (1998). Etiology and pathogenesis of primary pulmonary hypertension: A perspective. Chest., 114, supp 242S-247S.
10. Frid, M.G., Dempsey, E.C., Durmowicz, A.G. & Stenmark, K.R. (1997). Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Importance in vascular disease. Arterioscler. Thromb. Vasc. Biol., 17, 1203-1209.
11. Ghofrani, H.A., Wiedemann, R., Schermuly, R.T., Rose, F., Olschewski, H., Weissmann, N., Seegar, W. & Grimminger, F. (2002). Acute vasodilatory response to oral sildenafil (Viagra®) as compared to inhaled nitric oxide in pulmonary hypertension off different origin. Am. J. Crit. Care. Med., 165, A573.
12. Hanson, K.A., Ziegler. J.W., Rybalkin, S.D., Miller, J.W., abman, S.H. & Clarke, W.R. (1998). Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am. J. Physiol., 275, L931-L941.
13. Higashi, K., Fukunaga, K., Matsui, K., Maeyama, M. & Miyamoto, E. (1983). Purification and characterization of myosin light-chain kinase from porcine myometrium and its phosphorylation and modulation by cyclic AMP-dependent protein kinase. Biochim. Biophys. Acta., 747, 232-240.
14. Hong, H.J., Loh, S.H. & Yen, M.H. (2000). Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase. Br. J. Pharmacol., 131, 631-637.
15. Hunter, C., Barer, G.R., Shaw, J.W. & CLegg, E.J. (1974). Growth of the heart and lungs in hypoxic rodents: A model of human hypoxic disease. Clin. Sci. Mol. Med., 46, 375-391.
16. Le Cras, T.D., Xue, C., Rengasemy, A. & Johns, R.A. (1996). Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am. J. Physiol., 270, L164-L170.
17. Li, D., Zhou, N. & Johns, R.A. (1999). Soluble guanylate cyclase gene expression and localisation in rat lung after exposure to hypoxia. Am. J. Physiol., 277, L841-L847.
18. Lin, C., Lau, A., TU, R. & Lue, T.F. (2000). Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem. Biophys. Res. Comm., 268, 628-635.
19. MacLean, M.R. (1999a). Endothelin and serotonin in pulmonary hypertension. J. Lab. Clin. Med., 134, 105-114.
20. MacLean, M.R. (1999b). Pulmonary hypertension, anorexigens and 5-HT: Pharmacological synergism in action? Trends Pharmacol, Sci., 20, 490-495.
21. MacLean, M.R., Johnston, E.D., McCulloch, K.M., Pooley, L., Houslay, M. & Sweeney, G. (1997). Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: Changes in pulmonary hypertension. J. Pharmacol. Exp. Ther., 283, 619-624.
22. MacLean, M.R. & McCulloch, K.M. (1998). Influence of applied tension and nitric oxide on responses to endothelins in rat pulmonary resistance arteries. Br. J. Pharmacol., 123, 991-999.
23. MacLean, M.R., McCulloch, K.M. & Baird, M. (1995). Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6C and on inherent tone in rat pulmonary arteries. J. Cardiovasc. Pharmacol., 26, 822-830.
24. MacLean, M.R., Sweeney, G., Baird, M., McCulloch, K.M., Houslay, M. & Morecroft, I. (1996). 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br. J. Pharmacol., 119, 917-930.
25. Murray, K.J., England, P.J., Hallam, T.J., Maguire, J., Moores, K., Reeves, M.L., Simpson, A.W. & Rink, T.J. (1990). The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function. Br. J. Pharmacol., 99, 612-616.
26. Oka, M. (2001). Phosphodiesterase 5 inhibition restores impaired Ach relaxation in hypertensive conduit pulmonary arteries. Lung Cell. Mol. Pharmacol., 280, L432-L451.
27. Rabinovitch, M., Gamble, W., Nadas, A.S., Miettinen, O. & Reid, L. (1979). Rat pulmonary circulation after chronic hypoxia: Haemodynamic and structural features. Am. J. Physiol., 236, H818-H827.
28. Raychaudhuri, B., Dweik, R., Connors, M.J., Buhrow, L., Malur, A., Drazba, J., Arroliga, A.C., Erzurum, S.C., Kavuru, M.S. & Thomassen, M.J. (1999). Nitric oxide blocks nuclear factor kappaB activation in alveolar macropharges. Am. J. Respir. Cell. Mol. Biol., 21, 311-316.
29. Sanjay, P., WIlkinson, J. & Gatzoulis, M.A. (2000). Sildenafil in primary pulmonary hypertension. New Eng. J. Med., 343, 1342-1343.
30. Schermuly, R.T., Ghofrani, H.A, Enke, B., Weismman, N., Grimminger, F., Seeger, W., Schudt, C. & Walmrath, D. (1999). Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am. J. Resp. Crit. Care Med., 160, 1500-1506.
31. Schini-Kerth, V.B., Boese, M., Busse, R., Sisslthaler, B. & Mulsch, A. (1997). TLCK prevents expression of iNOS in vascular smooth muscle by blocking activation of NF-κB. Athero. Thromb. Vasc. Biol., 17, 672-679.
32. Soderling, S.H. & Beavo, J.A. (2000). Regulation of cAMP and cGMP: New phosphodiesterases and functions. Curr. Opin. Cell. Biol., 12, 174-179.
33. Thompson, W.J. & Appleman, M.M. (1971). Multiple cyclic nucleotide phosphodiesterase from brain. Biochemistry, 10, 311-316.
34. Wagner, R.S., Smith, C.J., Taylor, A.M. & Rhoades, R.A. (1997). Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J. Pharmac. Exp. Ther., 282, 1650-1657.
35. Ward, J.P. & Aaronson, P.I. (1999). Mechanisms of hypoxic pulmonary vasoconstriction: Can anybody be right? Respir. Physiol., 115, 261-271.
36. Weimann, J., Ullrich, R., Hromi, J., Fujino, Y., Clarke, M.W., Bloch, K.D. & Zapol, W.M. (2000). Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anaesthesiology, 92, 1702-1712.
37. Zhao, L., Mason, N.W., Morrell, N.W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M.M., Aldashev, A. & Wilkins, M.R. (2001). Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation, 104, 424-428.
38. Ziegler, J.W., Ivy, D.D., Fox, J.J., Kinsella, J.P., Clarke, W.R. & Abman, S.H. (1995). Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am. J. Physiol., 269, H473-H479.
39. Ziegler, J.W., Ivy, D.D., Wiggins, J.W., Kinsella, J.P., Clarke, W.R. & Abman, S. (1998). Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am. J. Resp. Crit. Care Med., 158, 1388-1393.